

## Supplemental

Approved for use through 7/31/2006. OMB 0651-0031  
**SUBSTITUTE for PTO/SB/03A (03-03). Information Disclosure Statement by Applicant  
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE**

<p>Substitute for form 1449A/PTO</p> <p><b>INFORMATION DISCLOSURE</b></p> <p><b>STATEMENT BY APPLICANT</b></p> <p><i>(use as many sheets as necessary)</i></p> <p><i>O I P E</i></p> <p><i>JUN 13 2005</i></p> <p><i>SEARCHED</i></p> <p><i>INDEXED</i></p> <p><i>MAILED</i></p> <p><i>TRADEMARK</i></p>		<b>COMPLETE IF KNOWN</b>	
		Application Number	10/797,257
		Filing Date	March 10, 2004
		First Named Inventor	Billot et al.
		Group Art Unit	1614
		Examiner Name	To be Assigned
Sheet	1	of	1
		Attorney Docket Number	MC080Y

## U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	9/7/2005
--------------------	---	-----------------	----------

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Complete separate form "IDS Form" (IDS Folder), Merit A Co., Inc., 202-292-2003.

**Substitute for form 1449AVTO**

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

50

1

of

3

COMPLETE IF KNOWN

<b>COMPLETE IF KNOWN</b>	
<b>Application Number</b>	10/797,257
<b>Filing Date</b>	March 10, 2004
<b>First Named Inventor</b>	Billot et al.
<b>Group Art Unit</b>	1614
<b>Examiner Name</b>	To be Assigned
<b>Attorney Docket Number</b>	MC080Y

## U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
EN	K.	WO 02/24647		A1	Ono Pharmaceutical	03/28/2002
	L.	WO 02/42268		A2	Pfizer Products Inc.	05/30/2002
	M.	EP 1114816		A1	Ono Pharmaceutical	07/11/2001
	N.	WO 01/46140		A1	Pfizer Products Inc.	06/28/2001
	O.	WO 03/105868		A1	Merck & Co. Inc.	12/24/2003
	P.	WO 03/105724			Merck & Co. Inc.	12/24/2003
	Q.	WO 03/105847		A1	Merck & Co. Inc.	12/24/2003
	R.	WO 02/060863		A1	Merck & Co. Inc.	08/08/2002
	S.	GB 1 524 818			Beecham Group Ltd.	11/29/1974
✓	T.	WO 01/72268		A2	Merck & Co.	10/03/2002

**Examiner  
Signature**

**Date Considered**

9/7/2005

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

Substitute for form 1449A/PTO

*(use as many sheets as necessary)*

## Sheet

2

of

3

**COMPLETE IF KNOWN**

Substitute for Form 1449A/PTO <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				<b>COMPLETE IF KNOWN</b>	
Application Number					
Filing Date					
First Named Inventor					
Group Art Unit					
Examiner Name					
Sheet	2	of	3	Attorney Docket Number	

## U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
XN	U.	WO 94/13275		A1	Massachusetts Eye and Ear Infirmary	06/23/1994
	V.	WO 01/70702		A1	Alcon Universal Ltd.	09/27/2001
	X.	WO 00/21542		A1	Merck & Co. Inc.	04/20/2000
	Y.	EP0855389		B1	Ono Pharmaceutical	01/26/1998
	Z.	WO 03/047417		A2	Merck & Co. Inc.	06/12/2003
	AA.	WO 03/047513		A2	Merck & Co. Inc.	06/12/2003
	BB.	EP 0 008 186		A1	Beecham Group Limited	07/30/1979
	CC.	WO 02/077168		A2	Merck & Co. Inc.	10/03/2002

**Examiner  
Signature**

**Date Considered**


9/4/2005

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated from "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				<b>COMPLETE IF KNOWN</b>	
				Application Number	10/797,257
				Filing Date	March 10, 2004
				First Named Inventor	Billot et al.
				Group Art Unit	1614
				Examiner Name	To be Assigned
Sheet	3	of	3	Attorney Docket Number	MC080Y

<b>NON PATENT LITERATURE DOCUMENTS</b>			
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.	
KK	DD.	P. Barracough et al., "Heterocyclic Prostagland Analoughes. Part 4, Piperazine-2,5-diones, Pyrazolidine-3,5-diones, 1,2,4-Triazolidinediones, 1,3,4-Oxadiazolidine-diones and 1,3,4-Thiadiazolidinediones", 1980, pp. 2096-2105, J.C.S. Perkin I.	
	EE.	R. A. Schumer et al., "The Nerve of Glaucoma", 1994, pp. 37-44, Vol. 112, Arch Ophthalmol.	
	FF.	M. Weinreb et al., "Different Pattern of Alkaline Phosphatase, Osteopontin, and Osteocalcin Expression in Developing Rate Bone Visualized by in Situ Hybridization", 1990, Vol. 5, No. 8, J. of Bone and Mineral Research.	
	GG.	D. A. Dartt et al., "Localization of Nerves Adjacent to Goblet Cells in Rat Conjunctiva" 1994, pp. 993-1000, Vol. 14, Curr. Eye Res.	
	HH.	L. Dandona et al., "Selective Effects of Experimental Glaucoma on Axonal Transport by Retinal Ganglion Cells to the Dorsal Lateral Geniculate Nucleus", 1991, pp. 1593-1599, Vol. 32, No. 5, Investigative Ophthalmology & Visual Sciences.	
	II.	E. M. Ross, "Mechanisms of Drug Action and the Realationship Between Drug Concentration and Effect", pp. 29-41, chapter 2, Goodman and Gilman's Pharmacological Basis of Therapeutics.	
	JJ.	I. K. Gipson et al., "Mucin Genes Expressed by the Ocular Surface Epithelium", 1997, pp. 81-98, Vol 16, No. 1, Progress in Retinal and Eye Research.	
	KK.	D. M. Shinar et al., "Expression of alphaV and Beta Integrin Subunits in Rat Osteoclasts in Situ", 1993, pp. 403-414, Vol. 8, No. 4, J. of Bone and Mineral Research.	
	LL.	M. A. Lemp et al., "Report of the National Eye Institute/Industry Workshop on Clinical Trials in Dry Eyes", 1995, pp. 221-232, Vol. 21, No. 4, CLAO Journal.	
	MM.	M. Abramovitz et al., "The Utilization of Recombinant Prostanoid Receptors to Determine the Affinities and Selectivities of Prostaglandins and Related Analogs", 2000, pp. 285-293, Vol. 1483, Biochimica et Biophysica Acta.	
	NN.	P. Chomczynski et al., "Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanante-Phenol-Chloroform Extraction", 1987, pp. 156-159, Vol. 162, Analytical Biochemistry.	
	OO.	S.B. Rodan et al., "Growth Stimulation of Rat Calvaria Osteoblastic Cells by Acidic Fibroblast Growth Factor", 1987, pp.1917-1923, Vol. 121, No. 6, Endocrinology.	
	PP.	M. Abramovitz et al., "Human Prostanoid Receptors: Cloning and Characterization", 1995, pp. 499-504, Vol. 23, Advances in Prostaglandin Thromboxane, and Leukotriene Research.	
	QQ.	J. E. Larco et al., "Epithelioid and Fibroblastic Rat Kidney Cell Clones: Epidermal Growth Factor (EGF) Receptors and the Effect of Mouse Sarcoma Virus Transformation", 1978, pp.335-342, Vol. 94, J. Cell Physiol.	
✓	RR.	T. J. Hodgkinson et al., "Practical Asymmetric Synthesis of Both Enantiomers of 6-(Hydroxymethyl) piperidin-2-one", pp. 1141-1144, Synthesis (1998)	

Examiner Signature		Date Considered	9/7/2005
--------------------	---	-----------------	----------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003